Literature DB >> 8886748

A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.

H Stracke1, A Lindemann, K Federlin.   

Abstract

In a double-blind, randomized, controlled study, the effectiveness of treatment with a combination of Benfotiamine (an Allithiamine, a lipid-soluble derivative of vitamin B1 with high bioavailability) plus vitamin B6/B12 on objective parameters of neuropathy was studied over a period of 12 weeks on 24 diabetic patients with diabetic polyneuropathy. The results showed a significant improvement (p = 0.006) of nerve conduction velocity in the peroneal nerve and a statistical trend toward improvement of the vibration perception threshold. Long-term observation of 9 patients with verum over a period of 9 months support the results. Therapy-specific adverse effects were not seen. The results of this double-blind investigation, of the long-term observation and of the reports in the literature support the contention that the neurotropic benfotiamine-vitamin B combination represents a starting point in the treatment of diabetic polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886748     DOI: 10.1055/s-0029-1211460

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  33 in total

Review 1.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

2.  Botulinum toxin type A combined with neurodynamic mobilization for lower limb spasticity: a case report.

Authors:  Jorge H Villafañe
Journal:  J Chiropr Med       Date:  2013-03

3.  Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence.

Authors:  Ann M Manzardo; Jianghua He; Albert Poje; Elizabeth C Penick; Jan Campbell; Merlin G Butler
Journal:  Drug Alcohol Depend       Date:  2013-08-11       Impact factor: 4.492

Review 4.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

5.  Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity.

Authors:  Ann M Manzardo; Tiffany Pendleton; Albert Poje; Elizabeth C Penick; Merlin G Butler
Journal:  Drug Alcohol Depend       Date:  2015-04-08       Impact factor: 4.492

Review 6.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 7.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 8.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy.

Authors:  Gordon Sloan; Dinesh Selvarajah; Solomon Tesfaye
Journal:  Nat Rev Endocrinol       Date:  2021-05-28       Impact factor: 43.330

9.  Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics.

Authors:  K K Kiew; W B Wan Mohamad; A Ridzuan; M Mafauzy
Journal:  Malays J Med Sci       Date:  2002-01

Review 10.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.